In the TME of BC, LILRB1 was predominantly expressed by infiltrating CD68+ macrophages 333, and was also notably upregulated in NK cells, particularly in patients with invasive BC relative to healthy donors and individuals with noninvasive (in situ) lesions 334, 335. Here, LILRB1 is linked to breast cancer.